To evaluate the overall response to desmopressin treatment among previously untreated enuretic children aged 5-15 years after 3 and 6 months of treatment.

To investigate the influence of possible predictive factors on response after 3 and 6 months of treatment.

To evaluate the proportion of patients achieving dryness. To evaluate the long-term safety profile of oral desmopressin in children with primary nocturnal enuresis.

To evaluate the overall response to desmopressin treatment among previously untreated enuretic children aged 5-15 years after 3 and 6 months of treatment.

To investigate the influence of possible predictive factors on response after 3 and 6 months of treatment.

To evaluate the proportion of patients achieving dryness. To evaluate the long-term safety profile of oral desmopressin in children with primary nocturnal enuresis.

Inclusion criteria:

• Children suffering from primary nocturnal enuresis with no organic pathology.
• Children of either sex, not below 5 and not above 15 years of age (not below 6 years in The Netherlands and France).
• Children with a minimum of 6 wet nights in 2 weeks.

Exclusion criteria:

• Children who have previously been treated with desmopressin or other medications for nocturnal enuresis or enuresis alarms.
• Children receiving substances that are known or suspected to potentiate antidiuretic hormone, e.g. SSRI, tricyclic antidepressant drugs, chlorpromazine and carbamazepine.
• Diagnosed renal diabetes insipidus or central diabetes insipidus with an AVP (arginine vasopressin) deficiency.
• Proven urinary tract infection within the past month or a documented positive urine culture at the start of the study